← Leaderboards

Bryan J Venters

Epicypher, Inc.

Google Scholar ↗PubMed ↗ORCID ↗

$11,553,129

Attributed

$18,482,693

Total exposure

10

Grants

7

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY2019–25

$5M$3.8M$2.5M$1.3M$0

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$18,482,693 · 10

By mechanism

R44$17,769,819 · 8

R43$712,874 · 2

Top collaborators

Most similar at Epicypher, Inc.

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Cells”

Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Evan Z Macosko · Broad Institute, Inc.$33,096,828
James Dale Berry · Brigham And Women'S Hospital$30,122,905
Hanjoon Ryu$28,519,898
Eric C Palm · Florida State University$26,502,247

Research focus

CellsChromatinNucleosomesInnovationProteinsServicesGenomicsHistonesValidationSamplingBar CodesTechnologyEpigenetic ProcessProtocols DocumentationMapsPost-Translational Protein ProcessingMonitorAntibodiesClinical ApplicationReagentTissuesRecombinantsResolutionDiagnostic

Grant awards (23)

Versatile platform for genome-wide R-loop mapping for aging and neurodegenerative disease research$1,274,958

R44 · FY2025 · AG · contact PI

Versatile genomics platform for unbiased analysis of chromatin-associated RNAs and nascent transcripts$1,267,289

R44 · FY2025 · AG

Epigenomic analysis of cell-free nucleosomes for cancer research$1,047,610

R44 · FY2025 · CA · contact PI

Versatile genomics platform for unbiased analysis of chromatin-associated RNAs and nascent transcripts$1,274,993

R44 · FY2024 · AG

Versatile platform for genome-wide R-loop mapping for aging and neurodegenerative disease research$1,274,632

R44 · FY2024 · AG · contact PI

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$1,032,776

R44 · FY2024 · HG

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$184,692

R44 · FY2024 · HG

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$1,035,703

R44 · FY2023 · HG

Epigenomic analysis of cell-free nucleosomes for cancer research$406,374

R43 · FY2023 · CA · contact PI

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$96,090

R44 · FY2023 · HG

Quantitative mapping of combinatorial histone modifications$1,024,752

R44 · FY2022 · HG

Development of efficient quantitative chromatin profiling in kit and high-throughput formats$1,020,317

R44 · FY2022 · HG · contact PI

Single-Cell Chromatin Mapping Assays$1,019,390

R44 · FY2022 · GM · contact PI

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$426,207

R44 · FY2022 · HG

Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping$103,580

R44 · FY2022 · HG

Single-Cell Chromatin Mapping Assays$1,024,878

R44 · FY2021 · GM · contact PI

Development of efficient quantitative chromatin profiling in kit and high-throughput formats$1,024,792

R44 · FY2021 · HG · contact PI

Quantitative mapping of combinatorial histone modifications$1,024,752

R44 · FY2021 · HG

Development of novel spike-in controls for quantitative chromatin-associated protein profiling$978,257

R44 · FY2021 · DE · contact PI

Development of ultra-efficient antibodies for single cell mapping applications$306,500

R43 · FY2021 · AI · contact PI

Development of novel spike-in controls for quantitative chromatin-associated protein profiling$978,257

R44 · FY2020 · DE · contact PI

Development of efficient quantitative chromatin profiling in kit and high-throughput formats$396,808

R44 · FY2020 · HG · contact PI

Development of novel spike-in controls for quantitative chromatin-associated protein profiling$259,086

R44 · FY2019 · DE · contact PI